Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Black Diamond Therapeutics (BDTX)
NASDAQ:BDTX
RESEARCH TOOLSreports
Black Diamond Therapeutics (BDTX) Stock Price & Analysis
706 Followers
BDTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.43 - $6.85
Previous Close$5.02
Volume355.98K
Average Volume (3M)644.23K
Market Cap
$259.62M
Enterprise Value$150.41M
Total Cash (Recent Filing)$131.40M
Total Debt (Recent Filing)$22.18M
Price to Earnings (P/E)-2.6
Beta2.93
Next Earnings
May 08, 2024EPS Estimate
-$0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.92
Shares Outstanding51,717,849
10 Day Avg. Volume629,093
30 Day Avg. Volume644,226
Standard Deviation0.36
R-Squared0.17
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)2.33
Price to Sales (P/S)228.14
Price to Cash Flow (P/CF)-4.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue132.17
Enterprise Value/Gross Profit132.17
Enterprise Value/Ebitda-1.83
Forecast
1Y Price Target
$13.50Price Target Upside169.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Black Diamond Therapeutics News
Bulls Say, Bears Say
Bulls Say
Drug Development ProgressBlack Diamond's BDTX-1535 demonstrates significant potential in treating various EGFR mutations in NSCLC, underscoring the drug's broad applicability and efficacy.
Financial StabilityBlack Diamond ended the year with a robust financial position, ensuring an operational runway well into the future.
Stock ValuationAnalysts are bullish on Black Diamond, raising the 12-month price target, signaling confidence in the company's growth prospects.
Bears Say
Clinical Trial UncertaintyAnalyst remains cautious about BDTX-1535's potential in treating glioblastoma multiforme due to historical challenges and unclear mutation response rates.
Drug Efficacy ConcernsAnalysts are cautious in ascribing value to BDTX-1535 in brain cancer due to historical challenges and the need for combination regimens to overcome resistance.
Financial PerformanceBDTX reported a net loss and further enrichment is likely needed to establish '1535 as a viable therapy in GBM.
---
Ownership Overview
63.79% Insiders
9.43% Mutual Funds
3.83% Other Institutional Investors
22.95% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
BDTX FAQ
What was Black Diamond Therapeutics’s price range in the past 12 months?
Black Diamond Therapeutics lowest stock price was $1.43 and its highest was $6.85 in the past 12 months.
What is Black Diamond Therapeutics’s market cap?
Currently, no data Available
When is Black Diamond Therapeutics’s upcoming earnings report date?
Black Diamond Therapeutics’s upcoming earnings report date is May 08, 2024 which is in 14 days.
How were Black Diamond Therapeutics’s earnings last quarter?
Black Diamond Therapeutics released its earnings results on Mar 12, 2024. The company reported -$0.34 earnings per share for the quarter, beating the consensus estimate of -$0.466 by $0.126.
Is Black Diamond Therapeutics overvalued?
According to Wall Street analysts Black Diamond Therapeutics’s price is currently Undervalued.
Does Black Diamond Therapeutics pay dividends?
Black Diamond Therapeutics does not currently pay dividends.
What is Black Diamond Therapeutics’s EPS estimate?
Black Diamond Therapeutics’s EPS estimate is -$0.43.
How many shares outstanding does Black Diamond Therapeutics have?
Black Diamond Therapeutics has 51,717,850 shares outstanding.
What happened to Black Diamond Therapeutics’s price movement after its last earnings report?
Black Diamond Therapeutics reported an EPS of -$0.34 in its last earnings report, beating expectations of -$0.466. Following the earnings report the stock price went down -5.5%.
Which hedge fund is a major shareholder of Black Diamond Therapeutics?
Among the largest hedge funds holding Black Diamond Therapeutics’s share is RA Capital Management. It holds Black Diamond Therapeutics’s shares valued at 10M.
---
Black Diamond Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.50 (169.46% Upside)
$13.50 (169.46% Upside)
Blogger Sentiment
Bullish
BDTX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 867.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.8%
Last 30 Days ▲ 0.6%
Last 30 Days ▲ 0.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
217.72%
12-Months-Change
Fundamentals
Return on Equity
-70.94%
Trailing 12-Months
Asset Growth
1.48%
Trailing 12-Months
Company Description
Black Diamond Therapeutics
Black Diamond Therapeutics, Inc. engages in the biotechnology company that discovers and develops therapeutic agents to target unique oncogenic protein-isoforms. The company was founded by Dr. David M. Epstein and Dr. Elizabeth Buck in 2014 and is headquartered in Cambridge, MA.
---
BDTX Stock 12 Months Forecast
Average Price Target
$13.50
▲(169.46% Upside)
Technical Analysis
Best Analysts Covering BDTX
1 Year
1 Year Success Rate
5/11 ratings generated profit
1 Year Average Return
+3.25%
reiterated a buy rating last month
Copying Robert Burns's trades and holding each position for 1 Year would result in 45.45% of your transactions generating a profit, with an average return of +3.25% per trade.
---